

Mortality among veterans with a diagnosis of pyruvate kinase deficiency: A real-world study using US Veterans Health Administration data

Erin Zagadailov, PharmD, MS¹ Audra N. Boscoe, PhD,¹ Viviana Garcia-Horton, PhD,² Sherry Shi, MSc,³ Shuqian Liu, MD,⁴ Lizheng Shi, PhD,⁴ Dendy Macaulay, PhD²

¹Agios Pharmaceuticals, Inc., Cambridge, MA, United States; ²Analysis Group, Inc., New York, NY, United States; ³Analysis Group, Inc., Montreal, QC, Canada; ⁴School of Public Health & Tropical Medicine, Tulane University, New Orleans, LA, United States

This study was funded by Agios Pharmaceuticals, Inc.

Introduction

Background

- Pyruvate kinase (PK) deficiency is a rare, inherited disorder caused by autosomal recessive mutations in the *PKLR* gene
 - A glycolytic defect causes reduced adenosine triphosphate levels and leads to hemolytic anemia
- Population-based studies of PK deficiency using claims or electronic health record databases are limited
 - Identifying PK deficiency in real-world data is challenging due to a lack of diagnosis codes and treatments that are specific to the disease
- Data on mortality in this patient population are lacking and limited to a few individual case reports^{1–9}
- The US Veterans Health Administration (VHA) database was selected for this research because of its long length of follow-up and availability of death data

Objectives

- Identify patients with a PK deficiency diagnosis as documented by physicians
- Compare their rates of mortality to an age- and gender-matched cohort of individuals without PK deficiency

Study Design

PK deficiency cohort

- Patients with ≥ 1 diagnosis code^a related to PK deficiency between January 1995 and July 2019 were selected from the US VHA database
- To be considered for inclusion, physicians' notes were required to contain the words "pyruvate", "kinase", and "deficiency"
- A manual review of these physicians' notes was performed to identify patients with a physician-documented diagnosis of PK deficiency
- The index date for the PK deficiency cohort was defined as the date of the first medical record with a diagnosis code related to PK deficiency

Non-PK deficiency cohort

- Each patient in the PK deficiency cohort was matched 1:5 by age at index, sex, and index year (± 1 year) to patients from the general VHA population with no diagnosis codes related to PK deficiency
- The index date for the non-PK deficiency cohort was defined as a random visit date during their match's index year

^aAnemia due to disorders of glycolytic enzymes (ICD-10-CM: D55.2), other hemolytic anemias due to enzyme deficiency (ICD-9-CM 282.3), or unspecified hereditary hemolytic anemia (ICD-9-CM 282.9, ICD-10-CM D58.9).
PK = pyruvate kinase; US = United States; VHA = Veterans Health Administration.

Data Analysis

Patient characteristics

- Demographic and clinical characteristics were compared between the PK deficiency cohort and their non-PK deficiency cohort matches

Survival analysis

- Survival time from the index date between the PK deficiency cohort and their non-PK deficiency cohort matches was summarized using Kaplan-Meier survival estimates and compared using a univariate Cox proportional hazards model with robust standard error estimation

Results


Patient characteristics

	PK deficiency cohort (N = 18)	Matched non-PK deficiency cohort (N = 90)
Age at index year, mean ± SD [median]	56.8 ± 13.6 [59.0]	56.8 ± 13.1 [59.0]
Category, n (%)		
20–30 years	1 (5.6)	5 (5.6)
30–40 years	0 (0.0)	0 (0.0)
40–50 years	5 (27.8)	25 (27.8)
50–60 years	4 (22.2)	20 (22.2)
60–70 years	7 (38.9)	35 (38.9)
70–80 years	0 (0.0)	0 (0.0)
80+ years	1 (5.6)	5 (5.6)
Male, n (%)	17 (94.4)	85 (94.4)
Region, n (%)		
South	6 (33.3)	6 (6.7)
Midwest	2 (11.1)	4 (4.4)
North east	7 (38.9)	48 (53.3)
West	3 (16.7)	32 (35.6)
White, n (%)	15 (83.3)	77 (85.6)
Weight (lbs), mean ± SD [median]	190.0 ± 42.4 [189.2]	206.2 ± 47.5 [195.0]
Height (in), mean ± SD [median]	69.3 ± 2.8 [69.9]	69.0 ± 2.9 [69.9]
BMI, mean ± SD [median]	27.6 ± 5.0 [26.7]	30.5 ± 6.7 [28.8]
20–25, n (%)	7 (38.9)	11 (12.2)
26–30, n (%)	5 (27.8)	37 (41.1)
> 30, n (%)	6 (33.3)	39 (43.3)
Charlson comorbidity index score, Mean ± SD [median]	0.4 ± 1.2 [0]	0.5 ± 1.2 [0]

- A total of 18 patients met inclusion criteria for the PK deficiency cohort and were matched to 90 individuals in the non-PK deficiency cohort
- The mean age at index was 57 years
- Imbalances remained between the two cohorts with regard to region (South) and body mass index (higher BMI in the non-PK deficiency cohort)

Results

Survival analysis



	PK deficiency cohort (N = 18)	Non-PK deficiency cohort (N = 90)
Years of follow-up, mean \pm SD [median]	7.3 \pm 5.2 [6.0]	9.2 \pm 5.8 [8.0]
Observed deaths over follow-up period, n (%)	9 (50%)	28 (31%)
Years until death, median	10.9	17.1

- Patients in the non-PK deficiency cohort had a significantly longer time to death than the PK deficiency cohort (hazard ratio: 2.3; $p = 0.0306$)
- 10 years after index, 42% of patients in the PK deficiency cohort had died compared with 28% of those in the non-PK deficiency cohort

Conclusion

- The results of this study suggest that patients with PK deficiency may be at an increased risk of mortality
- Further research is warranted to:
 - Understand cause of death among patients with PK deficiency
 - Examine mortality using larger sample sizes and other real-world data sources that better represent females and younger age groups

References

1. Alli N, Coetzee M, Louw V, van Rensburg B, Rossouw G, Thompson L, Pissard S, Thein SL. Sick cell disease in a carrier with pyruvate kinase deficiency. *Hematology*. 2008;13:369–72.
2. Nagai H, Takazakura E, Oda H, Tsuji H, Terada Y, Makino H, Yamauchi H, Saitoh K. An autopsy case of pyruvate kinase deficiency anemia associated with severe hemochromatosis. *Internal Medicine*. 1994;33:56–9.
3. Pérez-Albert P, Guillen M, Prudencio M, Gonzalez-Vicent M, Sevilla J. Trasplante de progenitores hematopoyéticos en déficit de piruvato cinasa: ¿cuándo indicarlo? *An Pediatr (Barc)*. 2018;88:106–7.
4. Pissard S, Max-Audit I, Skopinski L, Vasson A, Vivien P, Bimet C, Goossens M, Galacteros F, Wajcman H. Pyruvate kinase deficiency in France: a 3-year study reveals 27 new mutations. *British Journal of Haematology*. 2006;133:683–9.
5. Raphaël MF, Van Wijk R, Schweizer JJ, Schouten-van Meeteren NA, Kindermann A, van Solinge WW, Smiers FJ. Pyruvate kinase deficiency associated with severe liver dysfunction in the newborn. *American Journal of Hematology*. 2007;82:1025–8.
6. Rider NL, Strauss KA, Brown K, Finkenstedt A, Puffenberger EG, Hendrickson CL, Robinson DL, Muenke N, Tselepis C, Saunders L, Zoller H. Erythrocyte pyruvate kinase deficiency in an old-order Amish cohort: Longitudinal risk and disease management. *American Journal of Hematology*. 2011;86:827–34.
7. Zahid MF, Bains AP. Rapidly fatal *Klebsiella pneumoniae* sepsis in a patient with pyruvate kinase deficiency and asplenia. *Blood*. 2017;130:2906.
8. Zanella A, Berzuini A, Colombo MB, Guffanti A, Lecchi L, Poli F, Cappellini MD, Barosi G. Iron status in red cell pyruvate kinase deficiency: study of Italian cases. *British Journal of Haematology*. 1993;83:485–90.
9. Zanella A, Fermo E, Bianchi P, Chiarelli LR, Valentini G. Pyruvate kinase deficiency: the genotype-phenotype association. *Blood Reviews*. 2007;21:217–31.

Disclosures

- **Erin Zagadailov** – Agios – employee and stockholder; **Audra N. Boscoe** – Agios – employee and stockholder; **Viviana Garcia-Horton, Sherry Shi** – employed by Analysis Group, Inc., which received payment from Agios for participation in this research; **Shuqian Liu** – has a research contract and received consulting fees from Analysis Group, Inc., which received payment from Agios for participation in this research; **Lizheng Shi** – has a research contract and received consulting fees from Analysis Group, Inc., which received payment from Agios for participation in this research; **Dendy Macaulay** – employed by Analysis Group, Inc., which received payment from Agios for participation in this research.